Four names get thrown around constantly: Ozempic, Wegovy, Mounjaro, Zepbound. It sounds like four different things. It’s really two. Here’s the simple map.
Two medicines, four brand names
- Semaglutide is sold as Ozempic (the diabetes brand) and Wegovy (the weight-management brand). Same active ingredient.
- Tirzepatide is sold as Mounjaro (the diabetes brand) and Zepbound (the weight-management brand). Same active ingredient.
So if you line them up, it’s really semaglutide vs tirzepatide wearing four different name tags.
How they’re alike
Both belong to the same family we explain in GLP-1 medications, in plain English: they quiet appetite and help you feel full sooner. Both are weekly. Both are prescription-only.
How they differ
The main difference is the active ingredient. Tirzepatide works on two appetite-related pathways instead of one, and in studies it tended to show larger average weight change — but "bigger average" doesn’t mean "right for you." Side effects, cost, availability, and your medical history all matter, and they’re different for everyone.
So which is "best"?
There isn’t a universal winner. The best option is the one a licensed provider chooses with you after reviewing your health. Two people can walk in with the same goal and leave with different answers — and both can be correct.
See where you stand first
Ozempic and Wegovy are trademarks of Novo Nordisk; Mounjaro and Zepbound are trademarks of Eli Lilly. mybmi.ai is not affiliated with, endorsed by, or sponsored by either company. This article is educational and is not medical advice.